Calithera Biosciences, Inc. (NASDAQ:CALA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
2017 Performance Bonus Plan
On March7, 2017, the Board of Directors, upon the recommendation
of the Compensation Committee, approved our 2017 performance
bonus program for our named executive officers. The 2017 annual
performance bonuses for each named executive officer (as set
forth in our proxy statement for our Annual Meeting of
Stockholders held on June14, 2016), other than Dr.Susan
Molineaux, will be based upon the achievement of corporate
performance goals (80%)and individual performance goals (20%).
Dr.Susan Molineauxs annual performance bonus will be based solely
upon the achievement of corporate performance goals. The
corporate performance goals relate to the advancement of our
clinical trials and preclinical programs, business and corporate
development objectives, collaboration objectives and financial
management objectives. The individual performance goals will
consist of a subjective assessment of each named executive
officers individual contributions to Calithera. The following
table sets forth the base salary and target bonuses for 2017:
Bonus as a Percentageof
Total 2017 Target
Susan Molineaux, Ph.D.
President and Chief Executive Officer
Eric B. Sjogren, Ph.D.
Sr. Vice President, Drug Discovery
About Calithera Biosciences, Inc. (NASDAQ:CALA)
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Its lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. Hexokinase is an enzyme in the pathway that allows cancer cells to convert glucose to energy to fuel cancer cell growth. Calithera Biosciences, Inc. (NASDAQ:CALA) Recent Trading Information
Calithera Biosciences, Inc. (NASDAQ:CALA) closed its last trading session up +2.35 at 14.50 with 414,815 shares trading hands.